RRMS

Combination Therapy For Multiple Sclerosis Offers Promising Results In Recent Study

Positive study results from a preliminary phase II clinical trial for a new potential therapeutic intervention for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) were recently released at the American Academy of Neurology’s Annual Meeting in Philadelphia by Dr. Rhonda Voskuhl, M.D., from the University of California, Los Angeles.

Combined Multiple Sclerosis Therapy Using Copaxone Relieves RRMS Symptoms In Study

Although the biological activity by which Copaxone (glatiramer) exerts its effects i multiple sclerosis (MS) patients is not fully understood, it is believed it can block the induction of autoimmune encephalomyelitis as observed in recent experiments with mice.  Research in animals and in vitro systems suggest that glatiramer acetate-specific suppressor…

Targeting B-cell Activity May Reduce MS Brain Lesions, According To GlaxoSmithKline-Backed Study

New research work from GlaxoSmithKline presented by Daren Ausin, PhD, at the American Academy of Neurology’s 66th Annual Meeting has implications for individuals with relapsinig-remitting multiple sclerosis. The presentation detailed a study that used GlaxoSmithKline’s ofatumumab in 231 patients with relapse-remitting multiple sclerosis. Ofatumumab is an anti-B-cell antibody, and it…